Table 2.
Clinical and laboratory adverse events probably associated with the antimalarial treatment by study group that were recorded at least once during follow up.
| Adverse event1 | Amodiaquine/Placebo | Amodiaquine/Artesunate | ||
| N = 34 | (%) | N = 31 | (%) | |
| Leucopaenia | 18 | (52,9) | 13 | (41,9) |
| Neutropaenia | 16 | (47,1) | 15 | (48,4) |
| Anaemia | 10 | (29,4) | 7 | (22,6) |
| ALT> 48 U/L | 6 | (17,6) | 4 | (12,9) |
| Vomit | 5 | (14,7) | 2 | (6,5) |
| Dizziness | 5 | (14,7) | 6 | (19,4) |
| Abdominal pain | 5 | (14,7) | 4 | (12,9) |
| Bilirubin >1 mg/dL | 5 | (14,7) | 6 | (19,4) |
| Itching | 4 | (11,8) | 4 | (12,9) |
| Headache | 3 | (8,8) | 0 | (0) |
| Diarrhoea | 2 | (5,9) | 2 | (6,5) |
| Anorexia | 2 | (5,9) | 1 | (3,2) |
| Nausea | 1 | (2,9) | 3 | (9,7) |
1Definitions: leucopaenia (WBC<5,000/mm3), neutropaenia (total neutrophils<2,000/mm3), anaemia (haemoglobin <12 g/dL). ALT: Alanine Amino Transferase